Yazar "Namdaroglu, Sinem" seçeneğine göre listele
Listeleniyor 1 - 15 / 15
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Are mesenchymal stem cells still effective in acute GvHD management?(Pergamon-Elsevier Science Ltd, 2025) Ulu, Bahar Uncu; Hindilerden, Ipek Yonal; Yigenoglu, Tugce Nur; Tiryaki, Tarik Onur; Erkurt, Mehmet Ali; Korkmaz, Gulten; Namdaroglu, SinemObjective: Graft-versus-host disease (GvHD) is a common and serious complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), significantly impacting transplant efficacy. In the treatment of GvHD, numerous therapeutic approaches have been explored, with mesenchymal stem cells (MSCs) emerging as a prominent immunomodulatory option. We aimed to evaluate efficacy and outcomes of using MSCs for steroid refractory acute GVHD (SR-aGvHD) management. Materials and Methods: We retrospectively analyzed data from 36 patients' who received MSCs for treatment of SR-aGvHD following allo-HSCT between 2018 and 2024 from nine transplantation centers in T & uuml;rkiye. The product consisted of umbilical cord-derived allogeneic MSCs, which were administered intravenously. Results: Our cohort was at the median age of 39 years (range: 19-61 years), with aGvHD diagnosed at a median of two months after allo-HSCT. More than half of the patients (58.3%) classified as high-grade aGvHD according to the Minnesota risk scoring. Cord blood-derived MSCs were administered at a median dose of 3.45 (range: 0.8-5) million MSCs/kg, with a median of 3th (range: 2-5) line treatment. The rate of responses exceeding partial response (PR) was approximately 20% at the first month, increasing to 24% at the second month. The six-month survival rate was 33%, with 46% of mortality attributed to sepsis and 12.5% related to GvHD. Multivariate analysis indicated that increasing age (>= 35 years) and lower platelet counts (<= 75 x10(9)/L) were associated with higher mortality (p<0.05). Conclusion: MSC therapy has shown promising potential in improving response rates in aGvHD treatment, with efficacy enhanced by younger age and higher platelet counts.Öğe Convalescent plasma therapy in patients with COVID-19(Pergamon-Elsevier Science Ltd, 2021) Altuntas, Fevzi; Ata, Naim; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, SinemIntroduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and critically ill patients diagnosed with COVID-19. Method: The data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody-containing CP along with the antiviral treatment (n = 888) and an age-gender, comorbidity, and other COVID-19 treatments matched severe or critically ill COVID-19 patients at 1:1 ratio (n = 888) were analyzed retrospectively. Results: Duration in the intensive care unit (ICU), the rate of mechanical ventilation (MV) support and vasopressor support were lower in CP group compared with the control group (p = 0.001, p = 0.02, p = 0.001, respectively). The case fatality rate (CFR) was 24.7 % in the CP group, and it was 27.7 % in the control group. Administration of CP 20 days after the COVID-19 diagnosis or COVID-19 related symptoms were associated with a higher rate of MV support compared with the first 3 interval groups (?5 days, 6-10 days, 11-15 days) (p=0.001). Conclusion: CP therapy seems to be effective for a better course of COVID-19 in severe and critically ill patients.Öğe Convalescent plasma therapy in patients withCOVID-19(Wiley, 2020) Yigenoglu, Tugce Nur; Hacibekiroglu, Tuba; Berber, Ilhami; Dal, Mehmet Sinan; Basturk, Abdulkadir; Namdaroglu, Sinem; Korkmaz, SerdalThere are currently no licensed vaccines or therapeutics for COVID-19. Anti-SARS CoV-2 antibody-containing plasmas, obtained from the recovered individuals who had confirmed COVID-19, have been started to be collected using apheresis devices and stored in blood banks in some countries in order to administer to the patients with COVID-19 for reducing the need of intensive care and the mortality rates. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID-19. CP may be an adjunctive treatment option to the anti-viral therapy. The protective effect of CP may continue for weeks and months. After the assessment of the donor, 200-600 mL plasma can be collected with apheresis devices. The donation interval may vary between countries. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVID-19. It could also be used for prophylactic purposes but the safety and effectiveness of this approach should be tested in randomized prospective clinical trials.Öğe COVID-19 clinical course and blood groups: Turkish population-based study(Tubitak Scientific & Technological Research Council Turkey, 2021) DAL, Mehmet Sinan; Ata, Naim; Altuntas, Fevzi; Basci, Semih; Yigenoglu, Tugce Nur; Korkmaz, Serdal; Namdaroglu, SinemBackground/aim: SARS-CoV-2 enters the cell through the binding of the S glycoprotein on the surface of the virus to the angiotensin-converting enzyme 2 (ACE-2) in the host cells and also SARS-CoV S protein binding to ACE-2 was inhibited by anti-A antibodies. The aim of the study was to investigate the relationship between blood groups and the course of COVID-19 in Turkey. Materials and methods: Laboratory confirmed COVID-19 patients aged 18 and over (n = 39.850) were randomized in age and sex -matched groups according to blood groups Results: Advanced age, male sex and blood group A were found to be related with increased rate of intensive care unit (ICU) admission (OR = 1.089, 95% CI: 1.085-1.093 for age; OR = 1.963, 95% CI: 1.737-2.218 for male sex; OR = 1.216, 95% CI: 1.023-1.446 for blood group A). When blood group O individuals were compared to non-O individuals, no significant difference was observed regarding the rate of hospital and ICU admission, mechanical ventilation (MV) support, length of hospital and ICU stay, and case fatality rate (CFR). The CFR in patients with blood group A, B, O, and AB were 2.6%, 2.2%, 3.1%, and 2.3%, respectively. There were no significant differences between Rh-negative and positive patients regarding the rate of hospital and ICU admission (p = 0.280 and p = 0.741, respectively), also the rate of MV support and CFR was similar (p = 0.933 and p = 0.417). Conclusion: Our study revealed that ABO and Rh blood groups do not have any impact on the rate of hospital admission, hospital and ICU stay, MV support, and CFR.Öğe COVID-19 in hematopoietic cell transplant recipients(Springernature, 2021) Altuntas, Fevzi; Ata, Naim; Yigenoglu, Tugce Nur; Basci, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, SinemIn this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.Öğe Does body mass index affect stem cell yield in healthy donors?(Pergamon-Elsevier Science Ltd, 2025) Yilmaz, Seda; Okumus, Nazik; Seyhan, Mert; Sahin, Rasim; Korkmaz, Gulten; Erkurt, Mehmet Ali; Namdaroglu, SinemObjectives: Hematopoietic stem cell transplantation is an important treatment for many benign and malignant diseases. Factors affecting the donor response to mobilization and thus hematopoietic progenitor cell yield have been investigated, but studies on donor body mass index are limited and contradictory. Our aim in our study was to investigate this situation. Material and methods: The data of a total of 665 healthy donors were analyzed and divided into 2 groups as body mass index (BMI) < 25 (group 1, n: 247) and >= 25 kg/m(2) (group 2, n: 418). In addition to demographic data, smoking, blood group, agent used for mobilization, number of days of apheresis, volume of blood processed, amount of product collected, complete blood count before mobilization and biochemical parameters were evaluated. Results: Group 1 consisted of 247 and group 2 consisted of 418 participants. Median age was 29 (18-66) years in group 1 and 37 (18-68) years in group 2. Median BMI was 22.49 (16.10-24.98) and 28.06 (25.00-48.27) kg/m(2), respectively. Male donors constituted 62.7 % in group 1 and 73.9 % in group 2. In group 2, the number of apheresis days was lower and the median CD34(+) stem cell count on the first day and in total was statistically significantly higher (7.1 x10(6)/kg and 7.58 x10(6)/kg, respectively). Conclusion: In healthy donors, CD34(+) stem cells were correlated with BMI, whereas no statistically significant difference was found between the groups in terms of smoking habit, blood group, granulocyte stimulating agent type, processed blood volume, non-lymphocyte and biochemical parameters other than LDH.Öğe Fresh and cryopreserved stem cell transplantation in myeloma patients: Does it make a difference on transplant outcomes?(Pergamon-Elsevier Science Ltd, 2025) Erkurt, Mehmet Ali; Yilmaz, Seda; Namdaroglu, Sinem; Demircioglu, Sinan; Sarici, Ahmet; Cirik, Salih; Koroglu, MustafaObjective: The standard approach for multiple myeloma patients eligible for transplantation includes 4-6 cycles of induction therapy, followed by autologous stem cell transplantation (aHSCT). The aHSCT process starts with stem cell mobilization and collection, followed by high-dose chemotherapy and reinfusion of the harvested stem cells. These cells can be infused fresh within 24-48 h post-collection or cryopreserved for future use. Herein we analyzed the outcomes of aHSCT patients receiving infusions of fresh versus cryopreserved hematopoietic stem cells. Materials and methods: This multicenter retrospective study analyzed 88 adult patients diagnosed with multiple myeloma who underwent aHSCT (n = 43 for cryopreserved; n = 45 for fresh infused group). Results: A total of 88 patients were included in the study. 39.7 % of patients were female and 60.3 % of patients were male. No correlation was observed between pre-mobilization disease status, mobilization regimen, and disease risk status as defined by the R-ISS system (p = 0.1, p = 0.8). The median neutrophil engraftment time was 10 days in the fresh group and 12 days in the cryopreserved group (p < 0.01). In contrast, the median platelet engraftment time was 12 days in the fresh group and 11 days in the cryopreserved group (p < 0.01). Engraftment was achieved in all patients included in the study. Conclusion: The shorter neutrophil engraftment time in the fresh group and the shorter platelet engraftment time in the cryopreserved group, along with successful engraftment in all patients, suggest that both options are reasonable within the MM aHSCT protocol.Öğe Is there a relationship between stem cell yield obtained from healthy donors and healthy donors' blood type?(Pergamon-Elsevier Science Ltd, 2025) Katircilar, Yavuz; Sahin, Abdulkadir; Aydin, Muruvvet Seda; Erer, Kerim; Erkurt, Mehmet Ali; Namdaroglu, Sinem; Yilmaz, SedaBackground and objectives: Factors affecting adequate mobilization and apheresis are critical for a good yield of hematopoietic stem cells (HSCs) in the final product. A female donor, advanced age, smoking, high lactate dehydrogenase levels, high absolute lymphocyte count at baseline were found to be inversely correlated to the number of harvested CD34+ cells. However, the data on whether there is a correlation between blood types A, B, AB, O and the number of harvested CD34+ cells is insufficient. The aim of this study is to investigate the effect of blood types on the stem cell yield in healthy donors. Material and methods: A total of 807 healthy donors from 10 centers in T & uuml;rkiye were included in this retrospective study. Donors were subdivided into four groups as A, B, AB, O by their blood types. These four groups were compared in terms of age, sex, ECOG performance score, smoking status, and the amount of harvested CD34+ stem cells. Results: The median age of the 807 healthy donors included in the study was 35 years (11-70). 256 (31.7 %) donors were female and 551 (68.2 %) donors were male. There were 349 donors in type A blood group, 134 in type B blood group, 53 in type AB blood group and 271 donors in type O blood group. The median amount of CD34+ cells in the total apheresis product was 7.67 x 106 per kg in type O blood group, 7.52 x 106 per kg in type A blood group, 7.2 x 106 per kg in type B blood group, and 7.45 x 106 per kg in type AB blood group. There was no statistically significant difference among the groups (p:0.673). Smoking was lower in the type B blood group with 29.1 % compared to the other groups. However, there was no statistically significant difference in total amount of CD34+ stem cells in the type B blood group who smoked less (p = 0.949). Conclusion: In our study in which we have retrospectively analyzed the effect of donor blood types on the efficiency of HSCs harvested from peripheral blood in healthy donors, no correlation was found between the blood types and the mobilization and amount of harvested CD34+ cells.Öğe Is there a relationship between vitamin D levels and graft versus host disease?(Pergamon-Elsevier Science Ltd, 2025) Yigenoglu, Tugce Nur; Ulu, Bahar Uncu; Namdaroglu, Sinem; Erkurt, Mehmet Ali; Sahin, Rasim; Okumus, Nazik; Yilmaz, SedaObjective: Vitamin D deficiency is common in adult patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT). Since vitamin D is an important regulatory factor for the immune system, vitamin D deficiency may have effects on antitumor activity, relapse rates, graft versus host disease (GVHD) occurrence and infection rates in allo-HSCT. We aimed to investigate the effects of vitamin D levels on the outcome of allo-HSCT. Material and methods: This study included 211 patients who underwent allo-HSCT at seven transplant centers in T & uuml;rkiye. The impact of pretransplant vitamin D level on overall survival (OS), relapse rate, GVHD occurrence and engraftment times was analyzed retrospectively Results: Pretransplant vitamin D levels were not related to the neutrophil engraftment day (p: 0.887), relapse rate (p: 0.433) and GVHD occurrence (p: 0.391). At a median follow-up of 14 months, OS was 84.8 % and median OS was not reached. Univariate Cox Regression analysis showed that higher levels of vitamin D (>12 ng/mL) affected the survival rates (p = 0.029) (HR: 0.392: 95 % CI: 10.170-0.907). Conclusion: In our study, pretransplant vitamin D levels were not related to GVHD occurrence, relapse rate and engraftment times. However, we found that higher levels of pretransplant vitamin D levels (threshold is 12 ng/ mL) were associated with increased survival. Further studies with a larger population are necessary to reveal the role of vitamin D in patients undergoing allo-HSCT.Öğe Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors(Sage Publications Ltd, 2020) Basci, Semih; Ata, Naim; Altuntas, Fevzi; Yigenoglu, Tugce Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, SinemIntroduction In this study, we aim to report the outcome of COVID-19 in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitor (TKI). Method The data of 16 laboratory-confirmed COVID-19 patients with CML receiving TKI and age, gender, and comorbid disease matched COVID-19 patients without cancer at a 3/1 ratio (n = 48), diagnosed between March 11, 2020 and May 22, 2020 and included in the Republic of Turkey, Ministry of Health database, were analyzed retrospectively. Results The rates of intensive care unit (ICU) admission, and mechanical ventilation (MV) support were lower in CML patients compared to the control group, however, these differences did not achieve statistical significance (p = 0.1, and p = 0.2, respectively). The length of hospital stay was shorter in CML patients compared with the control group; however, it was not statistically significant (p = 0.8). The case fatality rate (CFR) in COVID-19 patients with CML was 6.3%, and it was 12.8% in the control group. Although the CFR in CML patients with COVID-19 was lower compared to the control group, this difference did not achieve statistical significance (p = 0.5). When CML patients were divided into 3 groups according to the TKI, no significant difference was observed regarding the rate of ICU admission, MV support, CFR, the length of stay in both hospital and ICU (all p > 0.05). Conclusion This study highlights that large scale prospective and randomized studies should be conducted in order to investigate the role of TKIs in the treatment of COVID-19.Öğe The outcome of COVID-19 in patients with hematological malignancy(Wiley, 2021) Yigenoglu, Tugce N.; Ata, Naim; Altuntas, Fevzi; Basci, Semih; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, SinemIn this study, we aim to report the outcomes for COVID-19 in patients with hematological malignancy in Turkey. Data from laboratory-confirmed 188 897 COVID-19 patients diagnosed between 11 March 2020 and 22 June 2020 included in the Republic of Turkey, Ministry of Health database were analyzed retrospectively. All COVID-19 patients with hematological malignancy (n = 740) were included in the study and an age, sex, and comorbidity-matched cohort of COVID-19 patients without cancer (n = 740) at a 1:1 ratio was used for comparison. Non-Hodgkin lymphoma (30.1%), myelodysplastic syndrome (19.7%), myeloproliferative neoplasm (15.7%) were the most common hematological malignancies. The rates of severe and critical disease were significantly higher in patients with hematological malignancy compared with patients without cancer (P = .001). The rates of hospital and intensive care unit (ICU) admission were higher in patients with hematological malignancy compared with the patients without cancer (P = .023,P = .001, respectively). The length of hospital stay and ICU stay was similar between groups (P = .7,P = .3, retrospectively). The rate of mechanical ventilation (MV) support was higher in patients with hematological malignancy compared with the control group (P = .001). The case fatality rate was 13.8% in patients with hematological malignancy, and it was 6.8% in the control group (P = .001). This study reveals that there is an increased risk of COVID-19-related serious events (ICU admission, MV support, or death) in patients with hematological malignancy compared with COVID-19 patients without cancer and confirms the high vulnerability of patients with hematological malignancy in the current pandemic.Öğe Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers(Springer-Verlag Italia Srl, 2022) Basci, Semih; Ata, Naim; Altuntas, Fevzi; Yigenoglu, Tugce Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroglu, SinemPrevious studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course compared to the general population. However, no randomized study compared the clinical course of COVID-19 in patients with hematologic cancers to patients with solid cancers. Thus, in this study, we intend to reveal the outcome of COVID-19 in hematologic cancer patients and compare their outcomes with COVID-19 patients with solid cancers. The data of 926 laboratory-confirmed COVID-19 patients, including 463 hematologic cancer patients and an age-gender paired cohort of 463 solid cancer patients, were investigated retrospectively. The frequencies of severe and critical disease, hospital and ICU admission, MV assistance were significantly higher in hematologic cancer patients compared with the solid cancer patients (p = 0.001, p = 0.045, p = 0.001, and p = 0.001, respectively). The hospital stay was longer in patients with hematologic cancers (p = 0.001); however, the median ICU stay was 6 days in both groups. The case fatality rate (CFR) was 14.9% in patients with hematologic cancers, and it was 4.8% in patients with solid cancers, and there was a statistically significant difference regarding CFR between groups (p = 0.001). Our study revealed that COVID-19 patients with hematologic cancers have a more aggressive course of COVID-19 and have higher CFR compared to COVID-19 patients with solid cancers and support the increased susceptibility of patients with hematologic cancers during the outbreak.Öğe The effect of threosulfan-based versus busulfan-based preparation regimens on transplant outcomes(Pergamon-Elsevier Science Ltd, 2025) Candir, Burcu Aslan; Okumus, Nazik; Hindilerden, Ipek Yonal; Erkurt, Mehmet Ali; Namdaroglu, Sinem; Merter, Mustafa; Yilmaz, SedaBackground: Allogeneic hematopoietic stem cell transplantation is a curative therapy for malignant and nonmalignant hematologic disorders. Conditioning regimens, such as those based on busulfan, are utilized to promote engraftment. Busulfan-based regimens are commonly employed but exhibit significant toxicity, leading to interest in alternate drugs such as treosulfan, which may offer a superior safety profile while preserving efficacy. Methods: This retrospective study examined 240 adult patients diagnosed with acute myeloid leukemia or acute lymphoblastic leukemia who received allogeneic hematopoietic stem cell transplantation at nine transplantation centers in T & uuml;rkiye from 2010 to 2024. Patients underwent either a busulfan-based or treosulfan-based conditioning regimen. Results: Engraftment was effective in both groups, with neutrophil engraftment happening earlier in the busulfan group (13 days vs. 15 days, p = 0.001). The incidence of veno-occlusive disease was significantly higher in the busulfan group (10.1 % vs. 0.9 %, p = 0.002). Cytomegalovirus infections were more prevalent in the busulfan group (51.2 % vs. 26.1 %, p < 0.001). Acute graft versus host disease occurred more frequently in the busulfan group (27.9 % vs. 18.9 %, p = 0.128); nonetheless, this difference did not reach statistical significance. No significant differences in relapse rates were detected through the groups. The overall survival was not reached in the busulfan group, while the treosulfan group demonstrated an overall survival of 40 months. Conclusion: Treosulfan-based conditioning regimens demonstrate similar efficacy to busulfan-based regimens while presenting a more acceptable toxicity profile. Treosulfan-based regimens also show a lower occurrence of veno-occlusive disease and cytomegalovirus infections.Öğe The role of ruxolitinib in the management of acute GVHD(Pergamon-Elsevier Science Ltd, 2025) Namdaroglu, Sinem; Hidayet, Emine; Aydin, Muruvvet Seda; Erkurt, Mehmet Ali; Berber, Ilhami; Cinar, Olgu Erkin; Ozet, GulsumBackground and objectives: Following an allogeneic hematopoietic stem cell transplant (allo-HSCT), a primary cause of morbidity and mortality is still steroid-refractory acute graft-versus-host disease (SR-aGVHD). Recently, ruxolitinib, an oral inhibitor of JAK1 and JAK2, was approved for use in individuals suffering from SR-aGVHD. This study aimed to analyze the efficacy and toxicity of ruxolitinib in the real world. Material and methods: In the present study, we investigated the effectiveness and toxicity of ruxolitinib in patients with SR-aGVHD using a multicenter retrospective analysis. We enrolled 23 patients between 2018 and 2024 who received ruxolitinib treatment for SR-aGVHD. Results: The first response was acheived in a median of 28 days (range, 12-150). The overall response rate (ORR) for ruxolitinib therapy was 43.5% (10/23) after one month and 61 % (14/23) after two months, respectively. The median overall survival was 69 months. Reactivation of cytomegalovirus (26.1 %) and grade 3-4 anemia (30.4 %) were the two main side effects of ruxolitinib therapy. Seven patients (30.4 %) passed away following a follow-up of a median of six months (range 1-70). The reasons for death included sepsis (n = 2, 28.6 %), progression of aGVHD (n = 3, 42.8 %), and other reasons. Conclusion: Ruxolitinib has an ORR of 61 % for SR-aGVHD, making it a safe and effective therapy choice in realworld settings.Öğe What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?(Pergamon-Elsevier Science Ltd, 2025) Ulas, Turgay; Namdaroglu, Sinem; Hindilerden, Ipek Yonal; Erkurt, Mehmet Ali; Erer, Kerim; Yigenoglu, Tugce Nur; Tiryaki, Tarik OnurObjectives: In this study, we aimed to compare the engraftment days, graft versus host disease (GVHD) development, relapse and overall survival (OS) rates in patients using variable intensity conditioning regimens with two different post-transplant cyclophosphamide (PTCy) doses for hematological malignancies. Material and methods: We retrospectively analyzed 162 patients who have had PTCy at a dose of 25 mg/kg x 2 and 50 mg/kg x 2 between 2018 and 2024. Patients were divided in 2 groups; PTCy dose with 25 mg/kg x 2 (Group 1, n = 45) and PTCy dose with 50 mg/kg x 2 (Group 2, n = 117). The engraftment days, GVHD, relapse and OS rates were compared across groups. Results: All patients had myeloablative conditioning regimens and peripheral stem cell collected transplantation. 61.1 % of patients (n = 99) were alive at the end of the study (60 % (n = 27) in Group1 and 61.5 % (n = 72) in Group 2). In Group 1 the median follow-up was 6.9 months and in Group 2 this was 7 months; the median OS was 15.5 months in Group 1 and 49.5 months in Group 2 but this is not statistically significant (Log rank = 0.796). In Group 1, the engraftment times for platelets was 13 days, for neutrophils 17 days; in Group 2, for platelet this was 18 days; and for neutrophils 17 days; this was statistically significant for platelets but not for neutrophil engraftment (p: < 0.001 and p:0.839, respectively). Eighteen patients (40 %) in Group 1 and twenty-seven (23 %) patients in group 2 had acute GVHD (aGVHD). In Group 1 aGVHD rates were higher than Group 2 (p = 0.031). Seven patients (15.5 %) in Group 1 and 6 (5.12 %) patients in group 2 had chronic GVHD (cGVHD). In Group 1 cGVHD rates were also higher than Group 2 (p = 0.048). Twenty-five patients (55.6 %) in Group 1 and 19 patients (16.2 %) in Group 2 had relapsed disease (p < 0.001). Conclusion: Our study showed that there were no differences in survival across the groups. The platelet engraftment time was shorter for the PTCy 25 mg/kg x 2 doses compared to the post-transplantation 50 mg/kg x 2 doses. Both aGVHD and cGVHD rates were higher in 25 mg/kg x 2 dose treated patients. Relapses occurred more commonly with 25 mg/kg x 2 PTCy dose.
